Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market
Executive Summary
Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.
You may also be interested in...
Further US Lawsuit Claims Price-Fixing Conspiracy
Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.
FDA Action Awaits Lupin Sites As Compliance Cloud Lingers
Lupin continues to face the heat for compliance deviations at its manufacturing plants, with the FDA now issuing an official action indicated inspection classification for two of the Indian company's sites. Lingering negative sentiment and remediation costs are some aspects that investors may need to brace for.
Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.